Unknown

Dataset Information

0

Comparison of 2 Different Paclitaxel-Coated Balloons in Coronary In-Stent Restenosis: A Randomized Controlled Trial.


ABSTRACT:

Background

Drug-coated balloons (DCBs) offer an effective treatment for in-stent restenosis (ISR). The Genoss DCB is a novel paclitaxel-coated balloon with a shellac plus vitamin E excipient that enhances drug delivery to the target lesion, minimizing restenosis.

Objectives

This study aimed to investigate the angiographic efficacy, clinical safety, and effectiveness of the novel shellac plus vitamin E-based DCB in a randomized controlled trial designed to enable regulatory approval of this new device in South Korea.

Methods

This noninferiority trial randomized patients experiencing their first ISR to the novel shellac plus vitamin E-based DCB or the reference SeQuent Please iopromide-based DCB in a 1:1 ratio. All patients underwent planned angiographic and clinical follow-up at 6 months. The study was powered for the primary endpoint of 6 months in-segment late lumen loss (LLL).

Results

A total of 82 patients from 7 centers were randomized to either the novel shellac plus vitamin E-based DCB group (n = 41) or the reference iopromide-based DCB group (n = 41). The 6-month in-segment LLL was 0.15 ± 0.43 mm with the novel DCB compared with 0.24 ± 0.39 mm with the reference device. The 1-sided 97.5% upper confidence limit of the difference was 0.13 mm, lower than the noninferiority limit of 0.29 mm, achieving noninferiority (P for noninferiority = 0.001). Major cardiovascular events were comparable between 2 groups at 6 months (7.7% for the novel DCB vs 10.3% for the reference DCB; P = 0.692).

Conclusions

In this multicenter, head-to-head comparison randomized trial, the novel shellac plus vitamin E-based DCB showed a comparable result to the reference iopromide-based device for the primary endpoint of 6-month in-segment LLL for the treatment of coronary ISR. (Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please in Korean Patient With Coronary In-stent Restenosis; NCT04405063).

SUBMITTER: Jun EJ 

PROVIDER: S-EPMC9627897 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Comparison of 2 Different Paclitaxel-Coated Balloons in Coronary In-Stent Restenosis: A Randomized Controlled Trial.

Jun Eun Jung EJ   Shin Eun-Seok ES   Yuan Song Lin SL   Bhak Youngjune Y   Garg Scot S   Kang Woong Chol WC   Kim Je Sang JS   Kim June-Hong JH   Bae Jang-Whan JW   Rha Seung-Woon SW   Chae In-Ho IH  

JACC. Asia 20220301 2


<h4>Background</h4>Drug-coated balloons (DCBs) offer an effective treatment for in-stent restenosis (ISR). The Genoss DCB is a novel paclitaxel-coated balloon with a shellac plus vitamin E excipient that enhances drug delivery to the target lesion, minimizing restenosis.<h4>Objectives</h4>This study aimed to investigate the angiographic efficacy, clinical safety, and effectiveness of the novel shellac plus vitamin E-based DCB in a randomized controlled trial designed to enable regulatory approva  ...[more]

Similar Datasets

| S-EPMC10924708 | biostudies-literature
| S-EPMC11775799 | biostudies-literature
| S-EPMC4841852 | biostudies-literature
| S-EPMC4870051 | biostudies-other
| S-EPMC11681599 | biostudies-literature
2023-03-02 | GSE217550 | GEO
| S-EPMC5226992 | biostudies-literature
| S-EPMC11539716 | biostudies-literature
| S-EPMC4184901 | biostudies-literature
| S-EPMC7431892 | biostudies-literature